Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent

Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent

The PD-1:PD-L1 immune checkpoint axis is central in the escape of cancer cells from anticancer immune responses. Monoclonal antibodies (mAbs) specific for PD-L1 have been approved for treatment of various cancer types. Although PD-L1 blockade has proven its merit, there are still several aspects tha...

Full description

Bibliographic Details
Main Authors: Katrijn Broos, Quentin Lecocq, Catarina Xavier, Jessica Bridoux, Tham T. Nguyen, Jurgen Corthals, Steve Schoonooghe, Eva Lion, Geert Raes, Marleen Keyaerts, Nick Devoogdt, Karine Breckpot
Format: Article
Language:English
Published: MDPI AG 2019-06-01
Series:Cancers
Subjects:
cancer
immune checkpoint
PD-1
PD-L1
single domain antibody
nanobody
monoclonal antibody
avelumab
immunotherapy
T cell
Online Access:https://www.mdpi.com/2072-6694/11/6/872

Internet

https://www.mdpi.com/2072-6694/11/6/872

Similar Items